4242 Campus Point Court
Tocagen is developing first-in-class, broadly applicable product candidates for the treatment of cancer using our cancer-selective gene therapy platform built on retroviral replicating vectors, or RRVs, initially for patients with recurrent high grade glioma, or HGG.
Our broadly applicable product candidates are designed to activate a patient’s immune system against their own cancer from within.
At the core of our approach is a gene therapy platform that utilizes RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Our proprietary platform is designed to fight cancer through a combination of mechanisms without the autoimmune toxicities that patients commonly experience with other treatments. In other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ healthy tissue intact while the tumor is destroyed.
Stock Symbol: TOCA
Stock Exchange: NASDAQ
This animation demonstrates the proposed mechanism of action for Tocagen’s lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC, and is based primarily on preclinical data.
Toca 511 & Toca FC is an investigational therapy, which has not been proven to be safe or effective for any use and is not approved by the U.S. Food and Drug Administration or any other government agency.
Tocagen is developing broadly applicable, cancer-selective immunotherapy treatments for cancer, including high grade glioma, a type of brain cancer. The company’s lead product combines Toca 511 with Toca FC. The therapeutic regimen involves two discrete steps with Toca 511 given first followed by treatment with Toca FC.
95 articles with Tocagen
Tocagen Presents Updated Durable Complete Response Data from Phase I Trial of Toca 511 & Toca FC in Recurrent High-Grade Glioma
Tocagen today reported updated data demonstrating long-term durable responses, and the conversion of initial partial responses into complete responses, from a Phase I study of Tocagen's investigational product, Toca 511 & Toca FC, for the treatment of patients with recurrent high-grade glioma.
Complementary Preclinical Studies Published In Neuro-Oncology Demonstrate Immune Activation Mechanism Of Tocagen's Toca 511 & Toca FC
Tocagen Receives Breakthrough Therapy Designation From FDA For Toca 511 & Toca FC In Recurrent High Grade Glioma
Tocagen Release: Company Expands Toca 5, Phase II/III Clinical Trial For Recurrent Brain Cancer, To South Korea
First Patient Enrolled In Toca 6, Tocagen's Trial For Metastatic Cancers Evaluating Intravenously Delivered Toca 511 Virus
RiboMed Biotechnologies, Inc. And Tocagen Inc. Collaborate To Analyze Epigenetic Prognostic Markers, Including MGMT, In Recurrent Brain Tumors